{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR","groups":[{"description":"Part B: Patients with ALK+ relapsed/refractory neuroblastoma","id":"OG000","title":"Phase 2: Part B: PF-02341066 280 mg/m2/Dose BID"},{"description":"Part C: Patients with ALK+ relapsed/refractory ALCL","id":"OG001","title":"Phase 2: Part C: PF-02341066 280 mg/m2/Dose BID"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Part B and Part C participants with relapsed or refractory neuroblastoma or anaplastic large cell lymphoma (ALCL)","reportingStatus":"POSTED","timeFrame":"Up to 8 years","title":"Number of Participants (Relapsed or Refractory Neuroblastoma or Anaplastic Large Cell Lymphoma (ALCL)) With Response to Crizotinib","type":"SECONDARY","unitOfMeasure":"Participants"}